ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Inclusion Criteria:
Exclusion Criteria:
Ciudad de Buenos Aires, C1199ABB, Argentina
Ciudad de Buenos Aires, C1428, Argentina
Kamakura-shi, 247-8533, Japan
Kawasaki-shi, 216-8511, Japan
Sagamihara-shi, 252-0375, Japan
Navarra, 31190, Spain
Menemen/Izmir, 35665, Turkey (Türkiye)